Abstract
Background: This evidence-based guideline is an update of the 2005 American Academy of Neurology practice parameter on the treatment of essential tremor (ET). Methods: A literature review using MEDLINE, EMBASE, Science Citation Index, and CINAHL was performed to identify clinical trials in patients with ET published between 2004 and April 2010. Results and Recommendations: Conclusions and recommendations for the use of propranolol, primidone (Level A, established as effective); alprazolam, atenolol, gabapentin (monotherapy), sotalol, topiramate (Level B, probably effective); nadolol, nimodipine, clonazepam, botulinum toxin A, deep brain stimulation, thalamotomy (Level C, possibly effective); and gamma knife thalamotomy (Level U, insufficient evidence) are unchanged from the previous guideline. Changes to conclusions and recommendations from the previous guideline include the following: 1) levetiracetam and 3,4-diaminopyridine probably do not reduce limb tremor in ET and should not be considered (Level B); 2) flunarizine possibly has no effect in treating limb tremor in ET and may not be considered (Level C); and 3) there is insufficient evidence to support or refute the use of pregabalin, zonisamide, or clozapine as treatment for ET (Level U).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1752-1755 |
| Number of pages | 4 |
| Journal | Neurology |
| Volume | 77 |
| Issue number | 19 |
| DOIs | |
| State | Published - Nov 8 2011 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
- Arts and Humanities (miscellaneous)
Cite this
Evidence-based guideline update : Treatment of essential tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology. / Zesiewicz, T. A.; Elble, R. J.; Louis, E. D.; Gronseth, G. S.; Ondo, W. G.; Dewey, R. B.; Okun, M. S.; Sullivan, K. L.; Weiner, W. J.
In: Neurology, Vol. 77, No. 19, 08.11.2011, p. 1752-1755.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evidence-based guideline update
T2 - Treatment of essential tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology
AU - Zesiewicz, T. A.
AU - Elble, R. J.
AU - Louis, E. D.
AU - Gronseth, G. S.
AU - Ondo, W. G.
AU - Dewey, R. B.
AU - Okun, M. S.
AU - Sullivan, K. L.
AU - Weiner, W. J.
PY - 2011/11/8
Y1 - 2011/11/8
N2 - Background: This evidence-based guideline is an update of the 2005 American Academy of Neurology practice parameter on the treatment of essential tremor (ET). Methods: A literature review using MEDLINE, EMBASE, Science Citation Index, and CINAHL was performed to identify clinical trials in patients with ET published between 2004 and April 2010. Results and Recommendations: Conclusions and recommendations for the use of propranolol, primidone (Level A, established as effective); alprazolam, atenolol, gabapentin (monotherapy), sotalol, topiramate (Level B, probably effective); nadolol, nimodipine, clonazepam, botulinum toxin A, deep brain stimulation, thalamotomy (Level C, possibly effective); and gamma knife thalamotomy (Level U, insufficient evidence) are unchanged from the previous guideline. Changes to conclusions and recommendations from the previous guideline include the following: 1) levetiracetam and 3,4-diaminopyridine probably do not reduce limb tremor in ET and should not be considered (Level B); 2) flunarizine possibly has no effect in treating limb tremor in ET and may not be considered (Level C); and 3) there is insufficient evidence to support or refute the use of pregabalin, zonisamide, or clozapine as treatment for ET (Level U).
AB - Background: This evidence-based guideline is an update of the 2005 American Academy of Neurology practice parameter on the treatment of essential tremor (ET). Methods: A literature review using MEDLINE, EMBASE, Science Citation Index, and CINAHL was performed to identify clinical trials in patients with ET published between 2004 and April 2010. Results and Recommendations: Conclusions and recommendations for the use of propranolol, primidone (Level A, established as effective); alprazolam, atenolol, gabapentin (monotherapy), sotalol, topiramate (Level B, probably effective); nadolol, nimodipine, clonazepam, botulinum toxin A, deep brain stimulation, thalamotomy (Level C, possibly effective); and gamma knife thalamotomy (Level U, insufficient evidence) are unchanged from the previous guideline. Changes to conclusions and recommendations from the previous guideline include the following: 1) levetiracetam and 3,4-diaminopyridine probably do not reduce limb tremor in ET and should not be considered (Level B); 2) flunarizine possibly has no effect in treating limb tremor in ET and may not be considered (Level C); and 3) there is insufficient evidence to support or refute the use of pregabalin, zonisamide, or clozapine as treatment for ET (Level U).
UR - http://www.scopus.com/inward/record.url?scp=82955243943&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82955243943&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e318236f0fd
DO - 10.1212/WNL.0b013e318236f0fd
M3 - Article
C2 - 22013182
AN - SCOPUS:82955243943
VL - 77
SP - 1752
EP - 1755
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 19
ER -